KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Short term Debt: 2009-2024

Historic Short term Debt for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $1.8 billion.

  • Teva Pharmaceutical Industries' Short term Debt fell 99.07% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year decrease of 99.07%. This contributed to the annual value of $1.8 billion for FY2024, which is 6.52% up from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Short term Debt of $1.8 billion as of FY2024, which was up 6.52% from $1.7 billion recorded in FY2023.
  • Teva Pharmaceutical Industries' Short term Debt's 5-year high stood at $3.2 billion during FY2020, with a 5-year trough of $1.4 billion in FY2021.
  • Its 3-year average for Short term Debt is $1.9 billion, with a median of $1.8 billion in 2024.
  • In the last 5 years, Teva Pharmaceutical Industries' Short term Debt slumped by 55.27% in 2021 and then soared by 47.90% in 2022.
  • Yearly analysis of 5 years shows Teva Pharmaceutical Industries' Short term Debt stood at $3.2 billion in 2020, then crashed by 55.27% to $1.4 billion in 2021, then spiked by 47.90% to $2.1 billion in 2022, then dropped by 20.72% to $1.7 billion in 2023, then rose by 6.52% to $1.8 billion in 2024.